Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer

"Depending on the investigator's preference, the following standard of care fractionation schedules are recommended: 1x 18-22 Gy, 3x 9 Gy or 5x 6 Gy. Fractionated stereotactic radiotherapy is favoured in principle, but not mandated, for postoperative radiotherapy and for metastases with a diameter of \>20 mm or for \>4 brain metastases.~For patients randomised to Arm A, radiotherapy should be initiated within 14 days after randomisation."

"Systemic therapy follows the current standard of care, according to the type of the primary tumour.~* For patients with melanoma, with or without BRAF-mutation, systemic therapy consists of~ * an approved immune-checkpoint inhibition combination therapy (cohort 1a) or~ * an approved immune-checkpoint inhibition monotherapy (cohort 1b).~* For patients with NSCLC and a targetable oncogenic driver alteration (cohort 2a), systemic therapy consists of an approved targeted therapy (for example: EGFR-, ALK- or ROS1-targeted treatment).~* For patients with NSCLC without a targetable oncogenic driver alteration (cohort 2b), systemic therapy consists of an approved immune-checkpoint inhibition therapy (with or without chemotherapy)."